CClinicalTrials.gg
Sign In
CompletedNCT02563847Updated Sep 30, 2015

Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans

An interventional study of 0.52 g L-Tryptophan and 1.56 g L-Tryptophan in Endocrine System Diseases, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-30.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

With this study the investigators investigate the effects of amino acids (tryptophan in two different concentrations, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms.

02

Conditions studied

  • Endocrine System Diseases
03

In context

Endocrine System Diseases

307 studies on the registry are indexed under Endocrine System Diseases; 52 are open to participants now.

This study's enrollment of 20 is below the median of 69 across 216 interventional studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy normal weight subjects with a body-mass index of 19.0-24.9
  • Healthy obese subjects with a body-mass index of > 30
  • Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)
  • Age 18-40 years
  • Stable body weight for at least three months

Exclusion criteria

Exclusion Criteria:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness
  • History of gastrointestinal disorders
  • Food allergies
  • Pregnancy, breast feeding
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    0.52 g L-Tryptophan

    0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 0.52 g L-Tryptophan · Other: 50 mg 13C-sodium acetate

  • Active comparator
    1.56 g L-Tryptophan

    1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 1.56 g L-Tryptophan · Other: 50 mg 13C-sodium acetate

  • Active comparator
    1.56 g L-Leucine

    1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 1.56 g L-Leucine · Other: 50 mg 13C-sodium acetate

  • Active comparator
    50 g Xylitol

    50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 50 g Xylitol · Other: 50 mg 13C-sodium acetate

  • Active comparator
    75 g Erythritol

    75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 75 g Erythritol · Other: 50 mg 13C-sodium acetate

  • Placebo comparator
    75 g Glucose

    75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 75 g Glucose · Other: 50 mg 13C-sodium acetate

  • Placebo comparator
    Tap water

    300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube

    Dietary Supplement: 300 mL tap water · Other: 50 mg 13C-sodium acetate

Interventions

  • Dietary supplement0.52 g L-Tryptophan
  • Dietary supplement1.56 g L-Tryptophan
  • Dietary supplement1.56 g L-Leucine
  • Dietary supplement50 g Xylitol
  • Dietary supplement75 g Erythritol
  • Dietary supplement75 g Glucose
  • Dietary supplement300 mL tap water
  • Other50 mg 13C-sodium acetate
06

What researchers measure

Primary outcomes

  1. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of glucose

    Time frame: changes from baseline to three hours after treatment

  2. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of insulin are measured

    Time frame: changes from baseline to three hours after treatment

  3. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of glucagon are measured

    Time frame: changes from baseline to three hours after treatment

  4. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of glucagon-like Peptide (GLP-1) are measured

    Time frame: changes from baseline to three hours after treatment

  5. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of PYY are measured

    Time frame: changes from baseline to three hours after treatment

  6. Effect of different aminoacids and sugar alcohols on secretion of satiation hormones

    Plasma concentrations of cholecystokinin are measured

    Time frame: changes from baseline to three hours after treatment

Secondary outcomes

  1. Effect of different aminoacids and sugar alcohols on gastric emptying

    measured by C13 breath test

    Time frame: changes from baseline to four hours after treatment

07

Study locations

1 site
  • University Hospital Basel, Phase 1 Research Unit
    Basel, Switzerland
08

References and documents

Publications

  • Meyer-Gerspach AC, Hafliger S, Meili J, Doody A, Rehfeld JF, Drewe J, Beglinger C, Wolnerhanssen B. Effect of L-Tryptophan and L-Leucine on Gut Hormone Secretion, Appetite Feelings and Gastric Emptying Rates in Lean and Non-Diabetic Obese Participants: A Randomized, Double-Blind, Parallel-Group Trial. PLoS One. 2016 Nov 22;11(11):e0166758. doi: 10.1371/journal.pone.0166758. eCollection 2016. PubMed 27875537 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02563847
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Sep 30, 2015
Start date
May 2014
Primary completion
Mar 2015
Last update
Sep 30, 2015

Study contacts

Christoph Beglinger, Prof.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endocrine System Diseases→

Other studies from this sponsor

University Hospital, Basel, Switzerland

Start the discussion